摘要
Pitolisant作为一种选择性组胺3受体拮抗剂/反向激动剂,近年来在欧美被获准治疗伴或不伴猝倒的成人发作性睡病。多项动物实验及临床病例证实,Pitolisant通过激活组胺传递来减轻发作性睡病患者的猝倒和日间过度嗜睡,另外在阻塞性睡眠呼吸暂停(OSA)、癫痫、阻断可卡因或甲基苯丙胺引起的过度运动中也具有一定效果;同时,Pitolisant成瘾性和不良反应发生率低,有望成为治疗成人发作性睡病的一线用药。
Pitolisant,antagonist/inverse agonist of the histamine 3 receptor,is approved for the treatment of adults narcolepsy with or without cataplexy and excessive daytime sleepiness(EDS)in Europe and American recently.It has been approved with rats and clinical trials that pitolisant works by activating histaminergic delivery.It also effects on Obstructive Sleep Apnea(OSA),epilepsy,cocaine or methamphetamine blocker induced hyperkinesia.With minimal abuse potential and less side-effects,pitolisant may trend to be the first-class administration on adult narcolepsy.
作者
许丹
XU Dan(Sleep Clinic of Traditional Chinese Medicine,the First Hospital of Jilin University,Changchun 130021,China)
出处
《世界睡眠医学杂志》
2021年第5期923-926,共4页
World Journal of Sleep Medicine
